Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis
about
Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitorsSensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib eraOptimized Treatment Schedules for Chronic Myeloid LeukemiaGrowth of tyrosine kinase inhibitor-resistant Philadelphia-positive acute lymphoblastic leukemia: Role of bone marrow stromal cellsUsing functional genomics to overcome therapeutic resistance in hematological malignancies.Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation.Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALLRole of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia.BCR-ABL1 kinase domain mutations: methodology and clinical evaluation.Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments.Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools.Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis.Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.Current and future management of Ph/BCR-ABL positive ALL.Treatment of Young Adults with Acute Lymphoblastic Leukemia.Continuing challenges and current issues in acute lymphoblastic leukemia.Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.Management of Philadelphia chromosome-positive acute lymphoblastic leukemia.Upfront treatment with the first and second-generation tyrosine kinase inhibitors in Ph-positive acute lymphoblastic leukemia.Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults.Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status.Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in t
P2860
Q27025242-C3F5F90A-0D35-474E-81CE-B68E6B0F3327Q27310990-7E48BEC6-36CB-483E-AD8A-D6252F13E2ABQ28486093-1AAA2869-3E1A-4727-B9AD-07C398DA12C2Q28552787-A3241970-1265-4EE4-8717-00B13E0D9F53Q33597756-78652CFD-8445-4478-B879-FDB93DF8242AQ34401328-9BDE3FED-B695-485C-96EE-AC0206380F18Q35731623-886A6F20-6CE4-4B78-A68E-399FB214B632Q36130255-B1E9D8C0-75D8-4B83-8D79-4C5E33CCE424Q37376595-DA9587DF-B697-47CE-B7CF-2D212E444993Q37887580-F1023AF0-231C-48FA-88C6-33697377E509Q37974490-53AD3155-E609-4BCC-BD47-8B922C31CC99Q38005040-6A41E782-FA51-4AB4-828A-5685D84DEA30Q38023947-0690CAE5-2187-4D7E-8BB3-27D56A1C12EEQ38037648-7A6DC9A4-F2E8-4A9D-9117-C786E4672CDDQ38087930-E1FDD274-26E4-42B0-B432-2D5AA9217A8AQ38194585-8EF81F88-A771-4942-8041-33E09597CC4AQ39206217-DCD3B5A1-AE3B-48FF-82B1-777FA092D878Q39366299-49EB4FC5-5690-4594-AA1B-8358141E67F4Q39985910-A416ED94-1C60-4C1A-93CD-E6A7827B41C4Q40817830-1BABFE89-8C23-4312-B466-54911380ABDAQ47104794-9960CC23-3FAE-4905-8B60-3AC89F076771Q47710825-4A654158-00BF-4B96-9533-76B9DB63FFCEQ47810636-551D6B8F-A311-4B1E-9213-3CBA4A7BD40DQ48240827-85FCAD7D-CC47-4BB8-868F-0E9807BCB0C4Q51160378-5138B261-B2EF-4E4F-A539-DBEED2D14E96Q54304704-5CBDE919-3BAC-421C-A679-67FBB6BAA129Q54330255-CEF53BD8-3875-418A-AFE4-F62A4CA0963CQ56974816-2CEEEA53-EA7B-4C13-89AA-332C4324392F
P2860
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Philadelphia-positive acute ly ...... evels at the time of diagnosis
@ast
Philadelphia-positive acute ly ...... evels at the time of diagnosis
@en
Philadelphia-positive acute ly ...... evels at the time of diagnosis
@nl
type
label
Philadelphia-positive acute ly ...... evels at the time of diagnosis
@ast
Philadelphia-positive acute ly ...... evels at the time of diagnosis
@en
Philadelphia-positive acute ly ...... evels at the time of diagnosis
@nl
prefLabel
Philadelphia-positive acute ly ...... evels at the time of diagnosis
@ast
Philadelphia-positive acute ly ...... evels at the time of diagnosis
@en
Philadelphia-positive acute ly ...... evels at the time of diagnosis
@nl
P2093
P2860
P50
P1433
P1476
Philadelphia-positive acute ly ...... evels at the time of diagnosis
@en
P2093
Alessandra Gnani
Angela Poerio
Anna Guarini
Antonella Vitale
Giovanna Meloni
Loredana Elia
Sabrina Colarossi
Stefania Paolini
Valeria di Maio
P2860
P304
P356
10.3324/HAEMATOL.2010.034173
P50
P577
2010-12-29T00:00:00Z